Simple math illustrates the challenge facing U.S. taxpayers, consumers and insurers following the launch late last year of two expensive new drugs to treat hepatitis C. If all 3 million people ...

The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

(Reuters) - Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration decided not to lift a clinical hold it had placed on the firm's hepatitis C drug, sovaprevir, leaving an uncertain ...

Louisiana is communicating with CMS to explore a subscription-based payment model for hepatitis C treatments, according to a proposal the Louisiana Department of Health released this week. The health ...

Ten years ago, safe and effective treatments for hepatitis C became available. These pills are easy-to-take oral antivirals with few side effects. They cure 95% of patients who take them. The ...

Vaccine advisers to the US Centers for Disease Control and Prevention may vote this week to make a major change to the ...

WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth ...

New Haven drug developer Achillion Pharmaceuticals Inc. has launched its first human trial of one of its treatment for chronic hepatitis C. The company says the double-blind Phase 1 study of its ...

NEW YORK (Reuters) - A hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal trial of previously untreated patients, the company said on ...

The CDC's vaccine advisory committee could vote this week to change hepatitis B vaccine recommendations for children. Here's ...

Hepatitis B vaccines given at birth have essentially eliminated the disease in kids. A vote this week could upend that ...